此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

ORKA-001在中度至重度斑块型银屑病患者中的剂量范围研究 (EVERLAST-B)

2026年11月3日 更新者:Oruka Therapeutics, Inc.

一项关于ORKA-001在中度至重度斑块状银屑病患者中进行的多中心、随机、双盲、安慰剂对照、剂量范围探索研究

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.

研究概览

地位

主动,不招人

详细说明

This is a multicenter, randomized, double-blinded, placebo-controlled, dose ranging study designed to identify the optimal induction dosing regimen of ORKA-001 in approximately 160 adult participants with moderate-to-severe plaque psoriasis.

The study will evaluate the efficacy and safety of 3 induction dosing regimens of ORKA-001 compared to placebo and will include 3 maintenance regimens.

The study will consist of 4 periods:

  • Screening Period of up to 6 weeks
  • Induction Period of up to 28 weeks (Day 1 [Baseline] to Week 28)
  • Maintenance Period of up to approximately 72 weeks (Week 28 to Week 100)
  • Post-treatment Follow-up Period: Participants will have the option to enter the open-label extension (OLE) study. Participants who opt out of the OLE study and/or withdraw from the study must be followed for 48 weeks after the End of Treatment (EOT)/Early Termination (ET) visit.

研究类型

介入性

注册 (估计的)

160

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • British Columbia
      • Surrey、British Columbia、加拿大、V3R 6A7
        • Oruka Therapeutics Investigative Site
      • Surrey、British Columbia、加拿大、V3V 0C6
        • Oruka Therapeutics Investigative Site
    • New Brunswick
      • Fredericton、New Brunswick、加拿大、E3B 1G9
        • Oruka Therapeutics Investigative Site
    • Ontario
      • Ajax、Ontario、加拿大、L1S 7K8
        • Oruka Therapeutics Investigative Site
      • Markham、Ontario、加拿大、L3P 1X3
        • Oruka Therapeutics Investigative Site
      • Peterborough、Ontario、加拿大、K9J 5K2
        • Oruka Therapeutics Investigative Site
    • Quebec
      • Montreal、Quebec、加拿大、HZX 2V1
        • Oruka Therapeutics Investigative Site
      • Québec、Quebec、加拿大、G1V 4X7
        • Oruka Therapeutics Investigative Site
    • Baden-Wuerrtemberg
      • Heidelberg、Baden-Wuerrtemberg、德国、69120
        • Oruka Therapeutics Investigative Site
    • Hesse
      • Frankfurt am Main、Hesse、德国、60590
        • Oruka Therapeutics Investigative Site
    • Lower Saxony
      • Bad Bentheim、Lower Saxony、德国、48455
        • Oruka Therapeutics Investigative Site
    • Schleswig-Holstein
      • Kiel、Schleswig-Holstein、德国、24105
        • Oruka Therapeutics Investigative Site
    • Arizona
      • Phoenix、Arizona、美国、85032
        • Oruka Therapeutics Investigative Site
    • Arkansas
      • North Little Rock、Arkansas、美国、72117
        • Oruka Therapeutics Investigative Site
    • California
      • Los Angeles、California、美国、90045
        • Oruka Therapeutics Investigative Site
      • Los Angeles、California、美国、90024
        • Oruka Therapeutics Investigative Site
      • San Diego、California、美国、92123
        • Oruka Therapeutics Investigative Site
    • Florida
      • Miami、Florida、美国、33126
        • Oruka Therapeutics Investigative Site
    • Illinois
      • Rolling Meadows、Illinois、美国、60008
        • Oruka Therapeutics Investigative Site
    • Indiana
      • Plainfield、Indiana、美国、46168
        • Oruka Therapeutics Investigative Site
    • Maryland
      • Rockville、Maryland、美国、20850
        • Oruka Therapeutics Investigative Site
    • New York
      • Kew Gardens、New York、美国、11415
        • Oruka Therapeutics Investigative Site
    • North Carolina
      • Chapel Hill、North Carolina、美国、27516
        • Oruka Therapeutics Investigative Site
    • Ohio
      • Cleveland、Ohio、美国、44106
        • Oruka Therapeutics Investigative Site
      • Mason、Ohio、美国、45040
        • Oruka Therapeutics Investigative Site
    • Oregon
      • Portland、Oregon、美国、97201
        • Oruka Therapeutics Investigative Site
      • Portland、Oregon、美国、97210
        • Oruka Therapeutics Investigative Site
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • Oruka Therapeutics Investigative Site
    • Texas
      • Frisco、Texas、美国、75033
        • Oruka Therapeutics Investigative Site
      • Houston、Texas、美国、77004
        • Oruka Therapeutics Investigative Site
      • Webster、Texas、美国、77598
        • Oruka Therapeutics Investigative Site
    • Virginia
      • Norfolk、Virginia、美国、23502
        • Oruka Therapeutics Investigative Site
    • Barcelona
      • Badalona、Barcelona、西班牙、08916
        • Oruka Therapeutics Investigative Site
      • Barcelona、Barcelona、西班牙、08041
        • Oruka Therapeutics Investigative Site
    • Madrid
      • Madrid、Madrid、西班牙、28002
        • Oruka Therapeutics Investigative Site
      • Madrid、Madrid、西班牙、28046
        • Oruka Therapeutics Investigative Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Participants ≥ 18 years of age

  2. Have a diagnosis of plaque psoriasis for > 6 months

  3. Have moderate-to-severe chronic plaque psoriasis defined as:

    1. BSA ≥ 10%, and
    2. PASI ≥ 12, and
    3. IGA score of ≥ 3 on a 5-point scale
  4. Candidate for systemic therapy or phototherapy

  5. Women of childbearing potential must have a negative pregnancy test.

Exclusion Criteria:

  1. Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis
  2. Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
  3. History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
  4. A known hypersensitivity to any components of the ORKA-001 drug product
  5. Women who are breastfeeding or plan to breastfeed during the study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:(Induction Period - Arm 1) ORKA-001

Participants will receive 37.5 mg ORKA-001 per protocol Induction regimen.

ORKA-001 administered by subcutaneous (SC) injection

实验性的:(Induction Period - Arm 2) ORKA-001

Participants will receive 300 mg ORKA-001 per protocol Induction regimen.

ORKA-001 administered by subcutaneous (SC) injection

实验性的:(Induction Period - Arm 3) ORKA-001

Participants will receive 600 mg ORKA-001 per protocol Induction regimen.

ORKA-001 administered by subcutaneous (SC) injection

安慰剂比较:(Induction Period - Arm 4) Placebo

Participants will receive Placebo per protocol Induction regimen.

Placebo administered by subcutaneous (SC) injection

实验性的:(Maintenance Period - Arm 1) ORKA-001

Participants will receive 300 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response.

ORKA-001 administered by subcutaneous (SC) injection

实验性的:(Maintenance Period - Arm 2) ORKA-001

Participants will receive 600 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response.

ORKA-001 administered by subcutaneous (SC) injection

安慰剂比较:(Maintenance Period - Arm 3) Placebo

Participants will receive Placebo per protocol Maintenance regimen, based on protocol defined response.

Placebo administered by subcutaneous (SC) injection

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16
大体时间:Week 16

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 16

次要结果测量

结果测量
措施说明
大体时间
Proportion of Participants Who Achieve an IGA = 0 (Clear) at Week 16
大体时间:Week 16

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 16
Proportion of Participants Achieving 90% Reduction in PASI Score at Week 16
大体时间:Week 16

Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 16
Proportion of Participants Who Achieve an IGA = 0 (Clear) or 1 (Almost Clear) at Week 16
大体时间:Week 16

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 16
Proportion of Participants Maintaining 100% Reduction in PASI Score at Week 100
大体时间:Week 100

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 100
Proportion of Participants Maintaining an IGA = 0 (Clear) at Week 100
大体时间:Week 100

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 100
Proportion of Participants Maintaining 90% Reduction in PASI Score at Week 100
大体时间:Week 100

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 100
Proportion of Participants Maintaining an IGA = 0 (Clear) or 1 (Almost Clear) at Week 100
大体时间:Week 100

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 100
Proportion of Participants Maintaining 75% Reduction in PASI Score at Week 100
大体时间:Week 100

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 100
Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs)
大体时间:Day 1 through Week 100

Incidence of treatment adverse events, treatment adverse events of special interest, and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms

Day 1 through Week 100

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年12月3日

初级完成 (实际的)

2026年10月21日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2025年12月16日

首先提交符合 QC 标准的

2025年12月16日

首次发布 (实际的)

2025年12月18日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • ORKA-001-114

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅